Wiskott-Aldrich综合征的造血细胞移植:PIDTC报告
该研究分析1990至2018年间37家机构308例Wiskott-Aldrich综合征患者接受异基因造血细胞移植的结局,中位随访5.3年,5年总生存率87.2%、无事件生存率79.7%。移植时年龄≥5岁、供者类型及移植前严重感染史对总生存率和无事件生存率有负面影响,而移植前自身免疫无影响。结论强调在严重感染发生前尽早移植,并确认基于白消安的预处理方案与供者嵌合及血小板恢复改善相关。
要点
- 308例WAS患者移植后5年OS为87.2%、EFS为79.7%,中位随访5.3年。
- 移植时年龄≥5岁、供者类型及移植前严重感染史与OS和EFS降低相关。
- 基于白消安的预处理与供者嵌合及血小板恢复改善相关,低髓系嵌合与低血小板计数相关。
核心结论
- 研究显示WAS患者接受HCT后具有优异的长期OS和EFS,强调在严重感染发生前尽早移植的重要性。
- 研究确认使用基于白消安的预处理方案进行HCT与供者嵌合和血小板恢复改善相关。
研究设计与样本
- 该研究为PIDTC多机构回顾性分析,纳入1990至2018年间37家机构308例接受HCT的WAS患者。
- 中位随访5.3年,评估5年OS、EFS及相关影响因素。
主要发现
- 5年OS为87.2%,5年EFS为79.7%。
- 移植时年龄≥5岁、供者类型及移植前严重感染史对OS和EFS有负面影响,而移植前自身免疫对OS和EFS无影响。
- 减低强度预处理方案与较低的T细胞和髓系供者嵌合相关,尤其在使用非白消安方案时。
- 低髓系供者嵌合与较低血小板计数相关。
- 混合嵌合与移植后自身免疫无一致相关性。
关键数值与推荐
- class I(外显子1-2错义及内含子5热点变异)与class II变异(所有其他变异)患者移植前临床症状严重程度相似,OS、EFS及移植后血小板恢复无差异。
临床怎么用
- 作者认为应重视在严重感染发生前尽早进行HCT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT and mismatched donors are known to affect overall survival (OS). However, the influence of specific clinical manifestations or WAS variant class on OS and factors associated with event-free survival (EFS) remain incompletely defined. We analyzed outcomes of 308 patients with WAS who underwent HCT at 37 institutions of the Primary Immune Deficiency Treatment Consortium from 1990 to 2018. With a median follow-up of 5.3 years, the 5-year OS and EFS were 87.2% and 79.7%, respectively. Age ≥5 years, donor type, and a pre-HCT history of severe infection had a negative impact on OS and EFS, whereas pre-HCT autoimmunity had no impact. Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non-busulfan-based regimens were used. Low myeloid donor chimerism was associated with lower platelet counts. Mixed chimerism was not consistently associated with post-HCT autoimmunity. Patients with class I (exon 1-2 missense and intron 5 hot spot variants) and class II variants (all others) had similar pre-HCT clinical symptom severity and no difference in OS, EFS, or platelet recovery post-HCT. In conclusion, our study showed excellent long-term OS and EFS after HCT for WAS, highlighting the importance of early HCT, before the development of severe infections. We confirmed that HCT using busulfan-based conditioning was associated with improved donor chimerism and platelet recovery. This trial was registered at www.clinicaltrials.gov as NCT02064933.
引用
- Alexander JL, Dávila Saldaña BJ, Brazauskas R, et al. Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood Adv. 2026. PMID: 41346295. doi:10.1182/bloodadvances.2025017662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。